Piramal Pharma Limited - Regulatory Clarification Response
Date and Nature of Exchange Query
This document is a clarification submitted by Piramal Pharma Limited to the National Stock Exchange of India Limited (NSE) on October 01, 2026. It is in response to a letter from the NSE (Ref. No.: NSE/CM/Surveillance/17636) dated September 30, 2026. The query sought clarification on a news item that appeared on 'www.thehindubusinessline.com' on September 30, 2026, titled "Ontario Contributes $1.7 Million Investment to Advance Life Sciences Innovation at Piramal Pharma's Aurora Facility."
Company’s Clarification on News and Trading
Piramal Pharma clarified that the news item pertained to funding support received by its Aurora facility from the Government of Ontario. The funding amount is CAD $1.7 million and is provided under the Life Sciences Scale-Up Fund (LSSUF) program. The program's objective is to support innovative Ontario-based life sciences companies in scaling operations and responding to procurement opportunities.
The company specified that the funding is intended for infrastructure upgrades, site modernization, improving operational efficiency, sustainability initiatives, and other enhancement projects at the Aurora facility. The project is also expected to contribute to employment generation and retention, support innovation and commercialization initiatives, and strengthen the broader life sciences and biomanufacturing ecosystem in Ontario.
Regarding any movement in the company's share price or trading volume, Piramal Pharma stated that it is not aware of any specific reason or information that may have resulted in such movement. The company attributes any observed movement to general market dynamics.
Reference to Regulatory Compliance
Piramal Pharma explicitly addressed the materiality of this event under SEBI regulations. The company concluded that this funding support does not constitute a material event or information requiring disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. This determination is based on the assessment that the funding is not expected to have a material impact on the Company's operations, financial position, or performance.